- Previous Close
20.94 - Open
20.75 - Bid 20.86 x 40000
- Ask 20.97 x 40000
- Day's Range
20.75 - 20.97 - 52 Week Range
14.52 - 26.00 - Volume
43,625 - Avg. Volume
145,476 - Market Cap (intraday)
68.947B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
27.93 - EPS (TTM)
0.75 - Earnings Date Jan 30, 2025
- Forward Dividend & Yield 0.27 (1.20%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
--
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jp7,604
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CHGCY
View More
Performance Overview: CHGCY
Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHGCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHGCY
View MoreValuation Measures
Market Cap
75.09B
Enterprise Value
69.87B
Trailing P/E
30.44
Forward P/E
28.25
PEG Ratio (5yr expected)
4.45
Price/Sales (ttm)
10.31
Price/Book (mrq)
6.72
Enterprise Value/Revenue
9.57
Enterprise Value/EBITDA
20.20
Financial Highlights
Profitability and Income Statement
Profit Margin
33.87%
Return on Assets (ttm)
17.37%
Return on Equity (ttm)
23.20%
Revenue (ttm)
1.14T
Net Income Avi to Common (ttm)
386.96B
Diluted EPS (ttm)
0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
845.32B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
290.7B
Research Analysis: CHGCY
View MoreCompany Insights: CHGCY
CHGCY does not have Company Insights